VivoSeq
Other

Heartburn

0

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Heartburn is an early-stage landscape with 0 programs across 5 companies. The most active players are AstraZeneca, Novartis, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

95/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed18 · 95%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Completed·Novartis logoNovartis·Phase 3·NCT00390390·576 enrolled
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00553449·48 enrolled
Efficacy of Esomeprazole in Patients With Frequent Heartburn
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT01370525·340 enrolled
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn
Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT01149395·40 enrolled
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
Completed·Novartis logoNovartis·Phase 3·NCT00389948·576 enrolled
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
Completed·Novartis logoNovartis·Phase 3·NCT00701259·852 enrolled
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
Completed·Takeda logoTakeda·Phase 3·NCT00627016·305 enrolled
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT01397084·107 enrolled
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan
Completed·—·Phase 4·NCT03079050·33 enrolled
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT01249651·101 enrolled
Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients
Completed·UUniversidade de Passo Fundo·Phase 3·NCT01065649·20 enrolled
Do Acid Sensing Ion Channels Contribute to Heartburn?
Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT01095133·24 enrolled
Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)
Completed·Bayer logoBayer·Phase 4·NCT01587885·48 enrolled
Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus
Completed·Bayer logoBayer·Phase 2·NCT04059900·64 enrolled
Efficacy of Esomeprazole in Patients With Frequent Heartburn
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT01370538·341 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)